Cargando…

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer

Because both vindesine and gemcitabine are active drugs in advanced non-small-cell lung cancer (NSCLC), with different modes of action and only partly overlapping toxicity, a phase II study was performed. Gemcitabine 1000 mg m(−2) was given on days 1, 8 and 15 every 4 weeks, while vindesine 3 mg m(−...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sørensen, J B, Bergman, B, Nielsen, A L, Krarup, M, Dombernowsky, P, Hansen, H H
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362682/ https://www.ncbi.nlm.nih.gov/pubmed/10070884 http://dx.doi.org/10.1038/sj.bjc.6690140

Ejemplares similares

A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.
por: Anderson, H., et al.
Publicado: (1996)

Biochemical effects of vindesine.
por: Creasey, W. A.
Publicado: (1981)

Cytotoxicity of etretinate and vindesine.
por: Gaukroger, J. M., et al.
Publicado: (1985)

An Open‐Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non‐Small Cell Lung Cancer
por: Patil, Pradnya Dinkar, et al.
Publicado: (2019)

Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
por: Lim, Sung Hee, et al.
Publicado: (2021)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression
por: Lassen, U N, et al.
Publicado: (1999)

Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2013)

Phase I study of 21 days continuous infusion with vindesine.
por: de Vries, E. G., et al.
Publicado: (1989)

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
por: Moorsel, C J A van, et al.
Publicado: (1999)

Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study
por: van Putten, J W G, et al.
Publicado: (2000)

Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial
por: Kooten, M Van, et al.
Publicado: (1999)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study
por: Douillard, J Y, et al.
Publicado: (2001)

Vindesine receptors in cells of a human leukaemia cell line.
por: Totsuka, K., et al.
Publicado: (1982)

Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses
por: Gridelli, C, et al.
Publicado: (2000)

A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine.
por: Evans, B. D., et al.
Publicado: (1982)

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer
por: Chen, H, et al.
Publicado: (2014)

Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801
por: Takayama, Koichi, et al.
Publicado: (2020)

A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
por: Nakano, T., et al.
Publicado: (1996)

A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01
por: Sahai, Vaibhav, et al.
Publicado: (2022)

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
por: McKeage, M J, et al.
Publicado: (2008)

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
por: Male, Christoph, et al.
Publicado: (2022)

Tallimustine in advanced previously untreated colorectal cancer, a phase II study.
por: Punt, C. J., et al.
Publicado: (1996)

Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer
por: Kinoshita, A, et al.
Publicado: (2006)

A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro.
por: Johnson, J. R., et al.
Publicado: (1981)

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
por: Lim, Sun Min, et al.
Publicado: (2023)

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
por: Amin, Asim, et al.
Publicado: (2016)

A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma
por: Morris, Don G., et al.
Publicado: (2006)

A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer.
por: Woods, R. L., et al.
Publicado: (1990)

Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate.
por: Embleton, M. J., et al.
Publicado: (1983)

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
por: Bekaii-Saab, Tanios, et al.
Publicado: (2023)

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer
por: Beretta, G D, et al.
Publicado: (2000)

Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.
por: Ford, C. H., et al.
Publicado: (1983)

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma
por: Scheithauer, W, et al.
Publicado: (1999)

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
por: Blackhall, F H, et al.
Publicado: (2001)

A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
por: Davis, S. Lindsey, et al.
Publicado: (2019)

A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)
por: Rasmussen, Louise Skau, et al.
Publicado: (2023)

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
por: Hu, Zishuo Ian, et al.
Publicado: (2019)

Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma
por: Ahn, Jae-Sook, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vdbja4sma15rdsesf4sea4gfog